Analysis of the causes and relief methods of fatigue during adagrasib (Krazati) medication

Adagrasiib (Krazati) is a KRAS G12Cselective inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. As a targeted therapy drug, Krazati blocks tumor cell proliferation by inhibiting the signaling pathway driven by KRAS G12C. However, during medication, some patients will experience varying degrees of fatigue or weakness, which affects their quality of life and requires scientific evaluation and intervention.

The occurrence of fatigue may be related to a variety of factors:

1.Direct effects of drugs:KRAS inhibition may affect cellular energy metabolism and mitochondrial function, leading to insufficient energy supply.

2.Tumor-related factors: Increased tumor burden and metabolic consumption may aggravate fatigue.

3.Indirect effects of drug side effects: such as nausea, loss of appetite, anemia or sleep disorders, which will aggravate patient fatigue.

For fatigue during medication, the following interventions can be taken:

1.Lifestyle adjustments: Ensure adequate sleep, regular work and rest, and moderate exercise, such as walking or light aerobic training, to help improve physical strength and endurance.

2.Nutritional support: maintain a high-protein, high-energy diet, supplemented by nutritional supplements when necessary.

3.Symptom monitoring and medication adjustment: If fatigue is severe, the doctor can evaluate whether to reduce the dosage or temporarily stop the medication, and at the same time correct the triggers such as anemia or electrolyte abnormalities.

In clinical practice, an individualized fatigue management plan should be established including regular assessment of physical status, hematological indicators and quality of life scores. For patients whose fatigue persists or worsens, complications or other adverse drug reactions should be ruled out, and psychological support and rehabilitation training should be combined if necessary. Scientific comprehensive management can ensure anti-tumor efficacy while maximizing fatigue relief and improving patients' long-term compliance and quality of life.

Reference materials:https://www.drugs.com/